{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:46Z","timestamp":1792791946439,"version":"4.5.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,29]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>More than half of patients with PV or ET harbor DNA mutations\/variants other than JAK2\/CALR\/MPL. The presence of some of these mutations adversely affects overall, leukemia-free, or myelofibrosis-free survival.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016000216","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T16:34:09Z","timestamp":1480523649000},"page":"21-30","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":296,"title":["Targeted deep sequencing in polycythemia vera and essential thrombocythemia"],"prefix":"10.1182","volume":"1","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"Finke","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Rotunno","sequence":"additional","affiliation":[{"name":"Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoseph","family":"Elala","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Pacilli","sequence":"additional","affiliation":[{"name":"Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pancrazzi","sequence":"additional","affiliation":[{"name":"Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Mannarelli","sequence":"additional","affiliation":[{"name":"Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Barraco","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Fanelli","sequence":"additional","affiliation":[{"name":"Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Centro Ricerca e Innovazione Malattie Mieloproliferative, Azienda Ospedaliera Universitaria Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2016,11,22]]},"reference":[{"issue":"7037","key":"2019111606354573100_B1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"5","key":"2019111606354573100_B2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111606354573100_B3","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"22","key":"2019111606354573100_B4","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111606354573100_B5","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111606354573100_B6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111606354573100_B7","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"14","key":"2019111606354573100_B8","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111606354573100_B9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms: A Contemporary Review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"key":"2019111606354573100_B10","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"7","key":"2019111606354573100_B11","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"15","key":"2019111606354573100_B12","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2019111606354573100_B13","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111606354573100_B14","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111606354573100_B15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111606354573100_B16","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111606354573100_B17","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2019111606354573100_B18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2013.286","article-title":"U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"2019111606354573100_B19","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"2019111606354573100_B20","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111606354573100_B21","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","article-title":"Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes","volume":"119","author":"Thol","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2019111606354573100_B22","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"50","key":"2019111606354573100_B23","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111606354573100_B24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/1\/21\/877387\/advances000216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/1\/21\/877387\/advances000216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T06:35:57Z","timestamp":1573886157000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/1\/21\/15513\/Targeted-deep-sequencing-in-polycythemia-vera-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,22]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,11,29]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016000216","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,22]]}}}